Showing results (11-20 of 25) with videos related to
Sort By:
Pageof 3
Proceedings of the National Academy of Sciences of the United States of America|October 24, 2009
Differential induction of apoptosis in HER2 and EGFR addicted cancers following PI3K inhibitionAnthony C Faber, Danan Li, Youngchul Song, et al.Blood Cancer Discovery|June 27, 2025
DLBCL cells emerge post CD19 CAR-T with cross-antigen resistance and a gene signature predictive of clinical CAR-T responseFabiana Lϋӧnd, Jeanne Whalen, Youngchul Song, et al.Cancer Research|March 11, 2010
An ErbB3 antibody, MM-121, is active in cancers with ligand-dependent activationBirgit Schoeberl, Anthony C Faber, Danan Li, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 21, 2014
Ponatinib inhibits polyclonal drug-resistant KIT oncoproteins and shows therapeutic potential in heavily pretreated gastrointestinal stromal tumor (GIST) patientsAndrew P Garner, Joseph M Gozgit, Rana Anjum, et al.Science (New York, N.Y.)|April 28, 2007
MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signalingJeffrey A Engelman, Kreshnik Zejnullahu, Tetsuya Mitsudomi, et al.Proceedings of the National Academy of Sciences of the United States of America|October 17, 2012
Combined targeting of HER2 and VEGFR2 for effective treatment of HER2-amplified breast cancer brain metastasesDavid P Kodack, Euiheon Chung, Hiroshi Yamashita, et al.Nature Medicine|November 26, 2008
Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancersJeffrey A Engelman, Liang Chen, Xiaohong Tan, et al.Cancer Cell|February 5, 2010
Preexistence and clonal selection of MET amplification in EGFR mutant NSCLCAlexa B Turke, Kreshnik Zejnullahu, Yi-Long Wu, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 21, 2012
Activation of PI3K signaling in Merkel cell carcinomaValentina Nardi, Youngchul Song, Juan A Santamaria-Barria, et al.Cancer Discovery|December 7, 2011
BIM expression in treatment-naive cancers predicts responsiveness to kinase inhibitorsAnthony C Faber, Ryan B Corcoran, Hiromichi Ebi, et al.Pageof 3